1628814-88-9
1628814-88-9 structure
- Name: Vobarilizumab
- Chemical Name: Vobarilizumab
- CAS Number: 1628814-88-9
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2018-07-01 21:00:51
- Modify Date: 2024-10-03 22:18:42
-
Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3].
| Name | Vobarilizumab |
|---|
| Description | Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Vobarilizumab 显示出对 sIL-6R 的优先结合亲和力 (与 mIL-6R 相比) [2]。 Vobarilizumab (0-10 nM) 阻断重组 hIL-6 与重组 hsIL-6R 的相互作用[3]。 Vobarilizumab (0-100 nM) 可抑制 TF-1 细胞的增殖[3]。 |
| In Vivo | Vobarilizumab (0.4-10 mg/kg，静脉注射) 抑制食蟹猴中 hIL-6 诱导的炎症[3]。 Vobarilizumab (0.4-10 mg/kg，静脉注射) 通过与食蟹猴的血清白蛋白结合显示出长期暴露[3]。 Animal Model: hIL-6-induced inflammation in cynomolgus monkey[3] Dosage: 0.4 mg/kg, 2 mg/kg, or 10 mg/kg Administration: Intravenous injection (i.v.) Result: Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets. Animal Model: Cynomolgus monkeys[3] Dosage: 0.4 mg/kg, 2 mg/kg, or 10 mg/kg Administration: Intravenous injection (i.v.) Result: Pharmacokinetic parameters of Vobarilizumab dose (mg/kg) T1/2 dominant (day) AUCinf (μg/day/mL) CL (mL/day/kg) Vss (mL/kg) 0.4 (i.v.) 1.73 16.3 24.8 42.8 2 (i.v.) 5.0 193 10.4 53.7 10 (i.v.) 6.61 1136 9 82.7 |
| References |
| No Any Chemical & Physical Properties |